疗前外周血NE值和LMR对局部进展期胃癌术前治疗后病理反应的预测价值

doi:10.3760/cma.j.cn113030-20200316-00104

摘要
图/表
参考文献
相关文章 (7)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的探讨局部进展期胃腺癌患者疗前多项血液指标对术前新辅助治疗后肿瘤病理反应的预测价值。方法回顾分析2013—2019年间一项多中心Ⅲ期临床试验中的 102例患者疗前外周血中性粒细胞(NE)、淋巴细胞(LY)和单核细胞(MO)绝对值。患者分为术前化疗组(3个疗程XELOX方案化疗)和术前放化疗组(XELOX诱导化疗1个疗程及4500cGy分25次放疗同期XELOX减量化疗2个疗程),各 51例。胃癌根治术后的肿瘤病理反应指标包括原发肿瘤消退等级、病理完全缓解、病理T和N分期(ypT和ypN)与TNM分期(ypTNM)。结果单因素回归模型及ROC曲线分析显示NE与ypT降期、LMR(LY/MO)与ypN0、LMR与ypTNM降期有显著相关性。多因素回归分析结果显示高NE组患者(>4.10×10⁹/L)有更高的ypT降期概率(OR=3.308,P=0.007);高LMR组(>3.46)有更高的ypN0概率(OR=4.276,P=0.005)与更高的ypTNM降期概率(OR=2.805,P=0.019)。亚组分析显示术前放化疗组中高NE组患者有更高的ypT降期概率(OR=3.750,P=0.030),而术前化疗组中高LMR患者有着更高的ypN0概率(OR=8.500,P=0.050)与肿瘤降期概率(OR=4.000,P=0.026)。结论疗前外周血NE和LMR可用作术前治疗后肿瘤病理反应的独立预测因素,患者免疫状态与局部晚期胃癌术前治疗后肿瘤退缩程度相关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李鼐
	张玉晶
	方艺
	张黎
	黄劭敏
	周志伟

关键词 ：胃肿瘤/放化疗法, 中性粒细胞绝对值, 淋巴细胞与单核细胞比值, 病理反应

Abstract：Objective To analyze the predicting values of hematological indicators for the pathological response in patients with gastric adenocarcinoma after preoperative neoadjuvant therapy and radical surgery. Methods The absolute count of neutrophils (NE), lymphocytes (LY) and monocytes (MO) of 102 patients with locally advanced gastric adenocarcinoma in a multi-center randomized phase Ⅲ clinical trial (NCT01815853) from June 2013 to Feburary 2019 were retrospectively analyzed. Patients were divided into the chemotherapy alone group (ChT, 3 cycles of XELOX regimen) and the chemoradiation group (CRT, 1 cycle of induced XELOX regimen and 4500 cGy/25f radiotherapy plus concurrent extenuated 2 cycles of XELOX regimen), 51 cases in each group. The pathological response indicators of tumors after radical surgery included tumor regression grade, pathological complete regression, pathological T stage (ypT), N stage (ypN) and TNM stage (ypTNM). Results Univariate regression analysis and ROC curves demonstrated a significant association between the absolute neutrophil count (NE) and ypT, lymphocyte-to-monocyte ratio (LMR) and ypN0, and LMR and ypTNM reduction in the entire cohort of patients. Multivariate regression analysis showed that higher NE (>4.10×10⁹/L) was significantly associated with higher probability of ypT reduction (OR=3.308, P=0.007). Higher LMR (>3.46) was significantly associated with higher ypN0 probability (OR=4.276, P=0.005) and better ypTNM reduction (OR=2.805, P=0.019). In subgroup analysis, higher NE (>4.10) was significantly correlated with higher probability of ypT reduction (OR=3.750, P=0.030) in the CRT group, and higher LMR (>3.46) was significantly associated with higher ypN0 probability (OR=8.500, P=0.050) and the probability of ypTNM stage reduction (OR=4.000, P=0.026) in the ChT group. Conclusions Pretreatment NE and LMR in the peripheral blood serve as independent predictors for tumor pathological responses after preoperative treatment, and immune condition is correlated with tumor regression after radical surgery in patients with locally advanced gastric cancer.

Key words： Gastric malignancy/chemoradiation therapy Absolute neutrophil count Lymphocyte-to-monocyte ratio Pathological response

收稿日期: 2020-03-16

基金资助:中山大学临床医学研究5010计划项目(2012013)

通讯作者: 张玉晶,Email:zhangyj@sysucc.org.cn

引用本文:

李鼐,张玉晶,方艺等. 疗前外周血NE值和LMR对局部进展期胃癌术前治疗后病理反应的预测价值[J]. 中华放射肿瘤学杂志, 2021, 30(4): 363-367.

Li Nai,Zhang Yujing,Fang Yi et al. The predicting value of pretreatment neutrophil count and lymphocyte-to-monocyte ratio in peripheral blood for the pathological tumor responses in patients with locally advanced gastric adenocarcinoma after preoperative therapy[J]. Chinese Journal of Radiation Oncology, 2021, 30(4): 363-367.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20200316-00104 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2021/V30/I4/363

[1] 王少明,郑荣寿,张思维,等.2015年中国胃癌流行特征分析[J]. 中华流行病学杂志,2019,40(12):1517-1521. DOI:10.3760/cma.j.issn.0254-6450.2019.12.003.
Wang SM, Zheng RS, Zhang SW, et al. Epidemiological characteristics of gastric cancer in China, 2015[J]. Chin J Epidemiol, 2019, 40(12):1517-1521. DOI:10.3760/cma.j.issn.0254-6450.2019.12.003.
[2] Man YG, Stojadinovic A, Mason J, et al. Tumor-infiltrating immune cells promoting tumor invasion and metastasis:existing theories[J]. J Cancer, 2013, 4(1):84-95. DOI:10.7150/jca.5482.
[3] Ying HQ, Deng QW, He BS, et al. The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients[J]. Med Oncol, 2014, 31(12):305. DOI:10.1007/s12032-014-0305-0.
[4] Wang QX, Li SH, Ji BY, et al. Lymphocyte/monocyte ratio is a novel predictor for early stage extranodal natural killer/T-cell lymphoma, nasal type[J]. J Cancer, 2017, 8(6):1030-1037. DOI:10.7150/jca.17400.
[5] Shimizu T, Taniguchi K, Asakuma M, et al. Lymphocyte-to-monocyte ratio and prognostic nutritional index predict poor prognosis in patients on chemotherapy for unresectable pancreatic cancer[J]. Anticancer Res, 2019, 39(4):2169-2176. DOI:10.21873/anticanres.13331.
[6] Gao XP, Liu YH, Liu ZY, et al. Pretreatment lymphocyte-to-monocyte ratio as a predictor of survival among patients with ovarian cancer:a meta-analysis[J]. Cancer Manag Res, 2019, 11:1907-1920. DOI:10.2147/CMAR. S184970.
[7] Robin X, Turck N, Hainard A, et al. pROC:an open-source package for R and S+ to analyze and compare ROC curves[J]. BMC Bioinform, 2011, 12(1):77. DOI:10.1186/1471-2105-12-77.
[8] 王修身,张羲茜,习勉,等. 食管鳞癌新辅助放化疗后淋巴细胞下降与病理反应相关性分析[J]. 中华放射肿瘤学杂志, 2019,28(4):274-279. DOI:10.3760/cma.j.issn.1004-4221.2019.04.006.
Wang XS, Zhang XQ, Xi M, et al. Correlation between treatment-related lymphopenia and pathologic response in esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoradiotherapy[J]. Chin J Radiat Oncol, 2019, 28(4):274-279. DOI:10.3760/cma.j.issn.1004-4221.2019.04.006.
[9] Galdiero MR, Bonavita E, Barajon I, et al. Tumor associated macrophages and neutrophils in cancer[J]. Immunobiology, 2013, 218(11):1402-1410. DOI:10.1016/j.imbio.2013.06.003.
[10] Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression:implications for new anticancer therapies[J]. J Pathol, 2002, 196(3):254-265. DOI:10.1002/path.1027.
[11] Abe S, Kawai K, Nozawa H, et al. LMR predicts outcome in patients after preoperative chemoradiotherapy for stage Ⅱ-Ⅲ rectal cancer[J]. J Surg Res, 2018, 222(1):122-131. DOI:10.1016/j.jss.2017.09.053.
[12] 李黎,李曙光,闫可,等. 外周血淋巴细胞与单核细胞比值变化对食管癌调强放疗预后影响[J]. 中华放射肿瘤学杂志,2019, 28(10):741-745. DOI:10.3760/cma.j.issn.1004-4221.2019.10.005.
Li L, Li SG, Yan K, et al. Effect of peripheral blood lymphocyte-to-monocyte ratio on prognosis of esophageal cancer patients treated with intensity-modulated radiotherapy[J]. Chin J Radiat Oncol, 2019, 28(10):741-745. DOI:10.3760/cma.j.issn.1004-4221.2019.10.005.
[13] Cheedella NK, Suzuki A, Xiao L, et al. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer:analysis in a large cohort[J]. Ann Oncol, 2013, 24(5):1262-1266. DOI:10.1093/annonc/mds617.
[14] Chen Z, Chen W, Wang J, et al. Pretreated baseline neutrophil count and chemotherapy-induced neutropenia may be conveniently available as prognostic biomarkers in advanced gastric cancer[J]. Intern Med J, 2015, 45(8):854-859. DOI:10.1111/imj.12786.
[15] Shen M, Hu P, Donskov F, et al. Tumor-associated neutrophils as a new prognostic factor in cancer:a systematic review and meta-analysis[J/OL]. PLoS One, 2014, 9(6):e98259. DOI:10.1371/journal.pone.0098259.
[16] Boustani J, Grapin M, Laurent PA, et al. The 6^th R of radiobiology:reactivation of anti-tumor immune response[J]. Cancers, 2019, 11(6):860-874. DOI:10.3390/cancers11060860.
[17] Martin-Romano P, Sola JJ, Diaz-Gonzalez JA, et al. Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer[J]. Br J Cancer, 2016, 115(6):655-663. DOI:10.1038/bjc.2016.252.